Articles

Texas Opens Detransition Clinic: Implications for Pharma

Texas has opened a detransition clinic, raising questions about its impact on the pharmaceutical landscape. This article explores key implications for B2B stakeholders.

From Reach to Relevance: Transforming Pharma Marketing Strategies

This article explores the shift in pharma marketing from mere reach to meaningful relevance, highlighting key strategies for B2B readers.

Regeneron Secures $125M Parabilis Deal for Drug Targets

Regeneron has entered a significant $125M deal with Parabilis to target elusive drug targets. This partnership could reshape competitive dynamics in the pharmaceutical industry.

Regeneron's Phase 3 Skin Cancer Miss: Implications for LAG-3 Development

Regeneron's recent Phase 3 trial failure in skin cancer highlights ongoing challenges in LAG-3 research. This article examines the implications for the pharmaceutical industry.

U.S. Bans Entry from Ebola-Affected Countries Amid Patient Identification

The U.S. has announced a travel ban from Ebola-affected countries following the identification of an American patient. This article explores the implications for the pharmaceutical sector.

Amgen's Commitment to Tavneos Amid Concerns in Japan

Amgen reaffirms its support for Tavneos despite a liver toxicity report from Japan. This article explores the implications for the pharmaceutical industry.

Trump's CMS Expands Catastrophic Coverage on ACA Exchanges

This article discusses the recent changes by Trump's CMS regarding ACA exchanges and their potential impact on the pharmaceutical sector.

AstraZeneca Secures FDA Approval for Hypertension Drug

AstraZeneca has gained FDA approval for its new hypertension drug, marking a significant milestone in the pharmaceutical industry. This approval opens new avenues for investment and competition.

Ebola Outbreak: Testing Long-Shot Vaccines Amid Crisis

As the Ebola outbreak continues, experts are considering testing unapproved vaccines. This article delves into the implications for the pharmaceutical industry.

Why the WakeMed – Atrium Health Merger Matters for Pharma

The merger between WakeMed and Atrium Health signals significant changes in the healthcare landscape, impacting pharmaceutical strategies and investments.

Enhertu's Dual FDA Approvals: A Game Changer in Early Breast Cancer Treatment

Daiichi and AstraZeneca's Enhertu has received dual FDA approvals for early breast cancer, marking a significant milestone in oncology. This article explores the implications for investors and pharma teams.

The Future of AI in Pharma Marketing

This article delves into CMI Media Group's predictions for AI in pharma marketing, highlighting key insights and implications for industry stakeholders.

Implications of CDER Leadership Changes at the FDA

The recent departure of CDER chief Tracy Beth Høeg raises questions about the future direction of the FDA and its impact on the pharmaceutical industry.

NICE Approves Imfinzi for Stomach Cancer: What It Means for Investors

NICE has approved Imfinzi for perioperative use in stomach cancer, just 17 days after UK approval. This article explores the implications for investors and pharma teams.

Wegovy Pill Scripts Decline: Implications for Pharma

The recent decline in Wegovy pill scripts marks a significant shift in the GLP-1 market. This article explores the implications for pharmaceutical companies and investors.

Navigating the New Policy Landscape in Pharma

Health executives are facing unprecedented challenges due to new policies. This article explores their strategies and implications for the pharma sector.

The Cloudy Truth About Blue Zones: Insights for Pharma

This article explores the complexities surrounding blue zones and their implications for the pharmaceutical sector, offering insights for business decision-makers.

Understanding the FDA: A Response to Marty Makary's Critique

This article examines the critiques made by Marty Makary regarding the FDA and clarifies key misunderstandings that could impact pharmaceutical strategies.

Doceree Launches Daily Command: An AI Revolution for Pharma Brand Teams

Doceree has unveiled Daily Command, an AI platform designed for pharma brand teams, co-developed with industry leaders. This innovation promises to enhance marketing effectiveness and decision-making.

When Should You Get a Mammogram? Navigating Conflicting Advice

Conflicting advice on mammogram timing creates uncertainty for patients and healthcare providers. This article unpacks the implications for pharma stakeholders.